Investigating ANS014004 for advanced solid tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase 1, first-in-human, open-label, multi-center study aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of ANS014004 in participants with locally advanced or metastatic solid tumors. The study will enroll adult patients who meet specific eligibility criteria, including having measurable disease and a pathogenetic MET alteration. Participants will receive ANS014004 as a single agent to assess its potential effectiveness and safety profile.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Eastern Cooperative Oncology Group (ECOG) Performance Status: 0-1
* Life expectancy ≥ 12 weeks
* Measurable disease per RECIST v1.1
* Adequate organ and marrow function as defined in the protocol
* With a pathogenetic MET alteration or ROS1 alteration or NTRK alternation

Exclusion Criteria:

* Active infection including tuberculosis and HBV, HCV or HIV
* Known active or untreated CNS metastases
* Participants with carcinomatous meningitis or meningeal metastases, or spinal cord compression
* Participants with serious cardiovascular or cerebrovascular diseases

Where it's running

• University of California, San Diego
  San Diego, California, United States Recruiting
• Sarah Cannon Research Institute
  Denver, Colorado, United States Recruiting
• Advent Health
  Orlando, Florida, United States Recruiting
• Henry Ford Health Cancer
  Detroit, Michigan, United States Recruiting
• NYU Langone Health
  New York, New York, United States Recruiting
• The University of Texas - MD Anderson Cancer Center
  Houston, Texas, United States Recruiting

Study contacts

• Study coordinator: Avistone Clinical Study Information Center
• Email: information.center@avistonebio.com
• Phone: 8610 84148921

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• ASP388B given alone or with standard therapies in solid tumors

  This early study tests ASP388B, first given alone or with standard cancer treatments, to see if it is safe and to find workable dose levels for solid tumors.

  Recruiting at 4 sites Phase 1/2 Astellas Pharma Inc · Lake Success, New York and 3 other locations · NCT07730021

• First-in-human test of EMB-15 in adults with advanced or metastatic solid tumors

  This early phase trial tests EMB-15 to see if it is safe and tolerable in adults whose solid tumors have progressed after standard care or have no standard therapy.

  Recruiting Phase 1 Shanghai EpimAb Biotherapeutics Co., Ltd. · Guangzhou, Guangdong · NCT07607054

• BC3195 plus pembrolizumab in advanced solid tumors

  This trial tests whether adding BC3195 to pembrolizumab is safe and shows preliminary activity in adults with locally advanced or metastatic solid tumors.

  Recruiting Phase 1/2 Biocity Biopharmaceutics Co., Ltd. · Guangzhou, Guangdong · NCT07469774

• YL202 for advanced non‑small cell lung, colorectal, cervical, and other solid tumors

  This trial will try YL202, an antibody‑drug conjugate that targets HER3, in adults with advanced non‑small cell lung, colorectal, cervical, or other metastatic solid tumors who have received one or two prior systemic treatments.

  Recruiting Phase 2 MediLink Therapeutics (Suzhou) Co., Ltd. · Changsha, Hunan · NCT07202364

• MRG007 (ARR-217) treatment for advanced solid tumors

  This trial will test MRG007 (ARR-217), an antibody-drug conjugate that targets CDH17, in adults with unresectable locally advanced or metastatic solid tumors who have exhausted standard therapies.

  Recruiting at 21 sites Phase 1 ArriVent BioPharma, Inc. · Los Angeles, California and 20 other locations · NCT07066657

• Evaluating XB010 for patients with solid tumors

  This study is testing a new drug called XB010, alone and with another medication, to see if it can help people with advanced solid tumors who have few other treatment options.

  Recruiting at 18 sites Phase 1 Exelixis · Irvine, California and 19 other locations · NCT06545331

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.